Literature DB >> 16763226

Switching statins.

James C Moon, Richard G Bogle.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16763226      PMCID： PMC1476712          DOI： 10.1136/bmj.332.7554.1344

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

2.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

Authors:  P Jones; S Kafonek; I Laurora; D Hunninghake
Journal:  Am J Cardiol       Date:  1998-03-01       Impact factor: 2.778

3.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

4.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Authors:  Peter H Jones; Michael H Davidson; Evan A Stein; Harold E Bays; James M McKenney; Elinor Miller; Valerie A Cain; James W Blasetto
Journal:  Am J Cardiol       Date:  2003-07-15       Impact factor: 2.778

5.  A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.

Authors:  Anders G Olsson; Mats Eriksson; Owe Johnson; Thomas Kjellström; Jan Lanke; Mogens Lytken Larsen; Terje Pedersen; Matti J Tikkanen; Olov Wiklund
Journal:  Clin Ther       Date:  2003-01       Impact factor: 3.393
  5 in total
  13 in total

1.  Switching statins: NICE tool overestimates benefits of statins.

Authors:  D Graham Mackenzie
Journal:  BMJ       Date:  2006-06-24

2.  Switching statins: cost of simvastatin is overestimated.

Authors:  John S Ashcroft
Journal:  BMJ       Date:  2006-06-24

3.  Switching statins: how to do it without tears and to benefit the NHS.

Authors:  Thomas Lau
Journal:  BMJ       Date:  2006-06-24

4.  How much will Herceptin really cost? The money is already there.

Authors:  Rubin Minhas
Journal:  BMJ       Date:  2006-12-09

5.  The Office of Fair Trading report: a prescription for value-based drug pricing.

Authors:  Rubin Minhas; James C Moon
Journal:  J R Soc Med       Date:  2007-05       Impact factor: 5.344

Review 6.  Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

Authors:  Brian Godman; Alan Haycox; Ulrich Schwabe; Roberta Joppi; Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

7.  Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.

Authors:  O Kenrik Duru; Susan L Ettner; Norman Turk; Carol M Mangione; Arleen F Brown; Jeffery Fu; Leslie Simien; Chien-Wen Tseng
Journal:  J Gen Intern Med       Date:  2013-08-22       Impact factor: 5.128

8.  Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.

Authors:  Pearl D Gumbs; W M Monique Verschuren; Patrick C Souverein; Aukje K Mantel-Teeuwisse; G Ardine de Wit; Anthonius de Boer; Olaf H Klungel
Journal:  Br J Clin Pharmacol       Date:  2007-09-13       Impact factor: 4.335

9.  Switching statins in Norway after new reimbursement policy: a nationwide prescription study.

Authors:  Solveig Sakshaug; Kari Furu; Øystein Karlstad; Marit Rønning; Svetlana Skurtveit
Journal:  Br J Clin Pharmacol       Date:  2007-04-18       Impact factor: 4.335

10.  Which interventions offer best value for money in primary prevention of cardiovascular disease?

Authors:  Linda J Cobiac; Anne Magnus; Stephen Lim; Jan J Barendregt; Rob Carter; Theo Vos
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.